Celularity Inc. Deferred Tax Assets, Net of Valuation Allowance
Celularity Inc. (CELU) had Deferred Tax Assets, Net of Valuation Allowance of $192.58 million as of 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-04-30
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $192.58M.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $181.42M.
- 2019-12-31: Deferred Tax Assets, Net of Valuation Allowance $1.65K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2025-12-31 | $192.58M 10-K · filed 2026-04-30 |
| 2024-12-31 | $181.42M 10-K · filed 2026-04-30 |
| 2019-12-31 | $1.65K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |